KORU Medical Systems, Inc. (KRMD) - Dilution Analysis

10-Q filing | 46.4M shares outstanding

10-K filing | 46.2M shares outstanding

10-Q filing | 46.2M shares outstanding

10-Q filing | 46.2M shares outstanding

10-Q filing | 46.0M shares outstanding

10-K filing | 45.8M shares outstanding

10-Q filing | 45.9M shares outstanding

10-Q filing | 45.8M shares outstanding

10-Q filing | 45.7M shares outstanding

10-K filing | 45.6M shares outstanding

8-K filing: KORU Medical Systems, Inc. issued a Stock Purchase Warrant to HSBC Ventures USA Inc. to purchase up to 76,104 shares of the Company's common stock at an exercise price of $2.12 per share as a condition to the closing of the Term Loan.

8-K filing: Kenneth Miller was appointed as the Chief Commercial Officer of KORU Medical Systems, Inc., commencing November 6, 2023, and will receive stock options as part of his employment agreement.

10-Q filing | 45.6M shares outstanding

10-Q filing | 45.6M shares outstanding

8-K filing: Andrew D. C. LaFrence was appointed Chief Financial Officer of KORU Medical Systems, Inc. commencing July 10, 2023, and will receive a non-qualified stock option to purchase up to 300,000 shares of the company's common stock.

S-3/A filing: This is an S-3/A filing for Koru Medical Systems, Inc. registering an indeterminate amount of common stock, preferred stock, debt securities and warrants with an aggregate offering price not to exceed $71,250,000.

S-3 filing: Koru Medical Systems files an S-3 registration statement to offer and sell up to $71,250,000 in various securities, including common stock, preferred stock, debt securities and warrants from time to time.

10-Q filing | 45.5M shares outstanding

10-K filing | 45.0M shares outstanding

10-Q filing | 45.0M shares outstanding

10-Q filing | 44.9M shares outstanding

10-Q filing | 44.7M shares outstanding

10-K filing | 44.4M shares outstanding

10-Q filing | 44.3M shares outstanding

10-Q filing | 44.5M shares outstanding

10-Q filing | 44.0M shares outstanding

10-K filing | 41.9M shares outstanding

8-K filing: Linda Tharby was appointed as the President and Chief Executive Officer of Repro Med Systems, Inc. effective April 12, 2021. She will receive a base salary of $550,000 and is eligible for bonuses and stock options.

10-Q filing | 41.3M shares outstanding

10-Q filing | 40.2M shares outstanding

8-K filing: Repro Med Systems, Inc. entered into a Purchase Agreement with underwriters to issue and sell 3,125,000 shares of its common stock, with an option for the underwriters to purchase an additional 468,750 shares, which was fully exercised, at a price of $7.52 per share, resulting in gross proceeds of approximately $28.8 million. ($28.8M proceeds)

8-K filing: Repro Med Systems, Inc. settled claims with EMED Technologies Corporation by issuing restricted stock units and an option to purchase common stock.

S-3 filing: Repro Med Systems, Inc. files an S-3 registration statement to offer and sell up to $100,000,000 of any combination of common stock, preferred stock, debt securities and warrants.

10-Q filing | 39.7M shares outstanding

POS AM filing: This is a post-effective amendment to a registration statement on Form S-1, converting it to Form S-3, and relates to the resale of up to 10,001,697 shares of common stock by selling stockholders.

10-K filing | 38.1M shares outstanding